ClinicalTrials.gg
RecruitingNCT06614894Updated Aug 20, 2025

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

A Phase 2/3 interventional study of Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day and Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day in Sanfilippo Syndrome and MPS3, sponsored by Ozlem Goker-Alpan. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Ozlem Goker-Alpan · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Mucopolysaccharidosis III with a site in United States — 12 open to participants now, 15 under way, 4 of them phase 3. Mucopolysaccharidosis III · United States.

Planned enrollment
16th of 23
10 · median 17
Started
2024
with 2 others
Phase 2/3
4 of 43
3 open now
Primary completion
2026-05
later than 2 of 14 live
Registered
40th of 43
by date

Among the 43 studies in Mucopolysaccharidosis III with a site in United States, this one is the 16th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2/3, reaches primary completion later than 2 of the 14 other live ones, and was the 40th registered.

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

Browse Mucopolysaccharidosis III studies →

Open to participants now

12 of the 43 studies in Mucopolysaccharidosis III with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Mucopolysaccharidosis III studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Mucopolysaccharidosis III with a site in United States, or all of them as a file.
02

Study summary

A dose escalation study to evaluate the safety, tolerability, and pharmacologic properties of Ambroxol in adult participants with Sanfilippo disease(s) (MPS3).

Read the detailed description

This is a dose escalation study in which open label Ambroxol 30mg (study drug) will be administered to adult patients with Sanfilippo Disease (MPS3). Administration route of study drug will be either crushed and mixed with soft foods or as an Ambroxol suspension through a feeding tube, if applicable.

Study Timeline - Screening: 4 weeks (28 days) Treatment Period: 52 weeks Post-Treatment (after Week 52): 4 weeks withdrawal/safety follow-up period

Patients will be screened at which point a thorough review of the Informed Consent form will be completed, sNFL levels, urinary GAGs, and serum HS results/data from the previous 12 months will be reviewed, urine and blood will be collected, complete questionnaires, Motor skills assessments, and evaluation by the Principal Investigator (PI).

Eligible patients will proceed to receive the initial Ambroxol dose of 9mg/kg/day (maximum dose of 150 mg TID) divided into three equal doses per day, on-site. Other assessments including blood and urine collection, ECG, motor skills assessments, hearing test, questionnaires, and evaluation by the PI will be completed.

Following the first day of dosing, a virtual visit will be performed via Telemedicine within 1 week of dose start to assess safety.

At Weeks 12 and 24, enrolled patients will return to site for Ambroxol dose escalation to 18mg/kg/day (max dose of 300 mg TID) and 27mg/kg/day (max dose of 1350 mg/day), respectively. Assessments including blood and urine collection, ECG, motor skills assessments, hearing test, questionnaires, and evaluation by the PI will be completed at these visits.

Telemedicine visits will take place at Weeks 13 and 25, to assess safety.

At Week 36, a safety visit will be performed in which blood and urine will be collected.

At Week 52, end of study assessments will be completed which includes blood and urine collection, motor skills assessments, hearing test questionnaires, and evaluation by the PI will be conducted and treatment will be stopped.

A safety follow-up visit will be done 4 weeks after Week 52 visit is completed in which the patient will be evaluated by the PI.

03

Conditions studied

  • Sanfilippo Syndrome
  • MPS3
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. IRB - approved /assent signed by subject and/or parent(s) or legal guardian(s).
  2. Genetically confirmed diagnosis of MPS III disease.
  3. Genomic DNA analysis demonstrating a homozygous or compound heterozygous pathogenic variants in SGSH (type A), NAGLU (type B), HGSNAT (type C), or GNS (type D) genes. Type E will not be studied.
  4. Elevated excretion of urinary GAGs and/or serum HS (if no historical data is available, screening GAGs and serum HS values will be utilized to assess inclusion criteria).
  5. Male or female; eighteen years of age and older, who is able to take Ambroxol Hydrochloride orally.
  6. Negative urine pregnancy test at screening for female subjects with .
  7. The subject is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of Ambroxol and for the duration of the treatment period.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to follow protocol requirements as per principal investigator.
  2. Any serious or chronic medical illness, including significant cardiac or severe debilitating pulmonary disease.
  3. Poorly controlled seizures, defined as more than one seizure per day for the past 6 months.
  4. Medications identified as a strong inducers or inhibitors of , and changing to another alternative drug to treat the condition would place the subject at undue risk.
  5. Any medical condition that, in the opinion of the PI, would make the subject unsuitable to participate in the study.
  6. Inability to cooperate for clinical and safety data collection.
  7. Known to Ambroxol or any of its .
  8. Use of genistein or Miglustat within one week of starting screening.
  9. Evidence of or infection upon serological testing at screening.
  10. Currently participating in another clinical trial or has completed an interventional trial less than 2 weeks prior to screening visit.
  11. The subject has received strong inducers (Note: eg, herbal supplements) or inhibitors of CYP3A within 15 days or 5 half-lives from screening, whichever is longer, prior to enrollment. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting Ambroxol administration.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Ambroxol Hydrochloride 30mg - 9mg/kg/day

    Ambroxol Hydrochloride 30mg Dose escalation: Initial dose of 9mg/kg/day (or max dose 150mg TID)

    Drug: Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day

  • Experimental
    Ambroxol Hydrochloride 30mg - 18mg/kg/day

    Ambroxol Hydrochloride 30mg Dose escalation: 18mg/kg/day (or max dose 300mg TID)

    Drug: Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day

  • Experimental
    Ambroxol Hydrochloride 30mg - 27mg/kg/day

    Ambroxol Hydrochloride 30mg Dose escalation: 27mg/kg/day (or max dose 1350mg QD)

    Drug: Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day

Interventions

  • DrugAmbroxol Hydrochloride 30 mg tablet - 9 mg/kg/day

    Drug page: AmbroxolStudies of AmbroxolAmbroxol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ambroxol Hydrochloride 30 mg oral pill/tablet - 9 mg/kg/day

    Also known as: Ambroxol

  • DrugAmbroxol Hydrochloride 30 mg tablet - 18 mg/kg/day

    Drug page: AmbroxolStudies of AmbroxolAmbroxol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ambroxol Hydrochloride 30 mg oral pill/tablet - 18 mg/kg/day

    Also known as: Ambroxol

  • DrugAmbroxol Hydrochloride 30 mg tablet - 27 mg/kg/day

    Drug page: AmbroxolStudies of AmbroxolAmbroxol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ambroxol Hydrochloride 30 mg oral pill/tablet - 27 mg/kg/day

    Also known as: Ambroxol

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    1\. Safety and tolerability as measured by number of Participants with at least one serious and at least one non-serious Treatment Emergent Adverse Events (TEAEs), assessed by CTCAE v4.0.

    Time frame: From baseline to 52 weeks

Secondary outcomes

  1. Changes in physical examination from baseline in motor capabilities and disease state: Physician (Clinician) Global Impression of Change

    Physician (Clinician) Global Impression of Change (scale: 0-very much worse - 7-Very much improved).

    Time frame: From baseline to 52 weeks

  2. Change from baseline in EQ-5D-5L™ or EQ-5D-Y™

    Change from baseline in EQ-5D-5L™ or EQ-5D-Y™

    Time frame: From baseline to 52 weeks

  3. Change from baseline in VABS-III age equivalent scores (AEqs)

    Vineland Adaptive Behavior scale-III

    Time frame: From baseline to 52 weeks

  4. Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III

    Plasma PK parameter estimates for oral Ambroxol include the area under the curve (AUC).

    Time frame: From baseline to 52 weeks

  5. Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III

    Plasma PK parameter estimates for oral Ambroxol include maximum concentration (Cmax).

    Time frame: From baseline to 52 weeks

  6. Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III

    Plasma PK parameter estimates for oral Ambroxol include time to maximum dose concentration (Tmax).

    Time frame: From baseline to 52 weeks

  7. Assessment of Pharmacokinetics of Ambroxol in subjects with MPS III

    Plasma PK parameter estimates for oral Ambroxol include terminal half-life (t1/2).

    Time frame: From baseline to 52 weeks

  8. Assessment of Pharmacodynamics of Ambroxol in subjects with MPS III

    Changes from baseline in Urinary GAG levels as measured by total quantified concentration. Changes from baseline will be analyzed using main effects, fixed for treatment (dose), categorical visit number, treatment-by-visit interaction, baseline value as covariate, and subject as the random effect.

    Time frame: From baseline to 52 weeks

  9. Assessment of Pharmacodynamics of Ambroxol in subjects with MPS III

    Serum Heparan sulfate (HS) level changes from baseline as measured by total quantified concentration. Changes from baseline will be analyzed using main effects, fixed for treatment (dose), categorical visit number, treatment-by-visit interaction, baseline value as covariate, and subject as the random effect.

    Time frame: From baseline to 52 weeks

  10. Change from baseline in Timed up and go (TUG) test

    Change from baseline in Timed up and go (TUG) test and in ABR at Week 52 may also be tested for correlations.

    Time frame: From baseline to 52 weeks

  11. Change from baseline in 10-meter walk test

    Change from baseline in 10-meter walk test, may also be tested for correlations.

    Time frame: From baseline to 52 weeks

  12. Change from baseline in SBRS

    Change from baseline in SBRS

    Time frame: From baseline to 52 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for May 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Sep 26, 2024
StartActual
Dec 1, 2024
Primary completionEst.
May 1, 2026
CompletionEst.
Jun 30, 2026
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06614894
Lead sponsor
Ozlem Goker-Alpan
Collaborators
Team Sanfilippo
Responsible party
Ozlem Goker-Alpan (Principal Investigator, Lysosomal and Rare Disorders Research and Treatment Center, Inc.) — Sponsor-investigator
First posted
Sep 26, 2024
Start date
Dec 1, 2024
Primary completion
May 1, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 20, 2025

Study contacts

Arooj Agha
Contact
aagha@ldrtc.org
571-732-4575
Lauren Noll
Contact
lnoll@ldrtc.org
571-732-4655
Ozlem Goker-Alpan, MD
principal investigator · Lysosomal & Rare Disorders Research & Treatment Center, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ambroxol

Start the discussion